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In Fetal Growth Restriction ‘fetal programming’ may take place via DNA methylation, which
has implications for short-term and long-term health outcomes. Small-for-gestational age
fetuses are considered fetal growth restricted, characterized by brain-sparing when fetal
Doppler hemodynamics are abnormal, expressed as a cerebroplacental ratio (CPR) <1. We
aimed to determine whether brain-sparing is associated with altered DNA methylation of
selected genes.
Methods
We compared DNA methylation of six genes in 41 small-for-gestational age placentas with a
normal or abnormal CPR. We selected EPO, HIF1A, VEGFA, LEP, PHLDA2, and DHCR24
for their role in angiogenesis, immunomodulation, and placental and fetal growth. DNA
methylation was analyzed by pyrosequencing.
Results
Growth restricted fetuses with an abnormal CPR showed hypermethylation of the VEGFA
gene at one CpG (VEGFA-309, p = .001) and an overall hypomethylation of the LEP gene,
being significant at two CpGs (LEP-123, p = .049; LEP-51, p = .020). No differences in meth-
ylation were observed for the other genes.
Conclusions
VEGFA and LEP genes are differentially methylated in placentas of small-for-gestational
age fetuses with brain-sparing. Hypermethylation of VEGFA-309 in abnormal CPR-pla-
centas could indicate successful compensatory mechanisms. Methylation of LEP-51 is
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known to suppress LEP expression. Hypomethylation in small-for-gestational age placentas
with abnormal CPR may result in hyperleptinemia and predispose to leptin-resistance later
in life.
Introduction
Fetal Growth Restriction (FGR) complicates 5 to 10% of all pregnancies and is a major risk fac-
tor for fetal and neonatal morbidity and mortality. Fetuses with an estimated fetal weight
<10th percentile for gestational age are commonly classified as small-for-gestational age
(SGA), however, many of these fetuses do reach their biological potential and are constitution-
ally small. Doppler assessment of fetal hemodynamics discerns between SGA and FGR. The
fetal vascular response to placental insufficiency, resulting in FGR is called “brain-sparing”, a
circulatory redistribution in which blood flow is preferentially shunted to the brain [1]. Brain-
sparing can be quantified with the cerebroplacental ratio (CPR), calculated as Middle Cerebral
Artery (MCA) Pulsatility Index (PI) divided by Umbilical Artery (UmbA) PI. As the name sug-
gests, brain-sparing is thought to be a beneficial adaptive mechanism to prevent brain damage
[2,3]. However, recent studies suggest that FGR fetuses with brain-sparing might be at an
increased risk for neurodevelopmental and behavioral deficits, such as reduced gross and fine
motor skills, and a reduced intelligence quotient [4].
Brain-sparing is indicating an adverse intrauterine condition that can lead to ‘fetal pro-
gramming’, which has implications for short-term as well as long-term health. This program-
ming can occur via alterations in DNA methylation, an epigenetic mechanism, which
regulates gene expression. Differential methylation and/or gene expression has been reported
in FGR for various genes, including those encoding for erythropoietin (EPO), hypoxia induc-
ible factor 1 alpha subunit (HIF1A), vascular endothelial growth factor A (VEGFA), leptin
(LEP), pleckstrin homology-like domain family A member 2 (PHLDA2) and 3-β-hydroxysterol
delta-24-reductase (DHCR24) [5–8]. In this study, we focused on methylation of these genes in
the placenta as they have profound roles in angiogenesis, neurodevelopment, immunomodula-
tion and placental and fetal growth.
The methylation status of angiogenic genes in the placenta is of interest because of the pos-
sible hypoxic state that the FGR fetus can encounter. This hypoxic stress drives activation of
angiogenic compensatory mechanisms such as EPO, HIF1A and VEGFA. EPO is expressed in
the placenta and supports the fetal condition by e.g. regulating fetal red blood cell production,
promoting erythroid differentiation and initiating hemoglobin syntheses [9]. HIF1A is a pro-
angiogenic regulator in the anti-hypoxic response [10]. In response to hypoxia, HIF1A binds
to the enhancer region of EPO and drives its expression [11]. The effect of HIF1A is favorable
in the acute phase but can become pathological if prolonged, e.g. in placenta dysfunction in
preterm preeclampsia (PE) [12]. VEGFA is an important regulator of angiogenesis which stim-
ulates placental endothelial cell proliferation [8]. Increased VEGFA expression has been found
in FGR placentas [8]. In preterm PE placentas, hypomethylation of VEGFA has been reported,
resulting in upregulated expression [13]. We hypothesized that methylation of EPO, HIF1A
and VEGFA in the placenta may play a role in the response to hypoxia and differs for fetuses
that show brain-sparing.
With respect to the presence of brain-sparing, we expect to see methylation changes in LEP,
PHLDA2 and DHCR24, as these genes are associated with neurodevelopment. LEP, commonly
known as the “hormone of energy expenditure”, is an important metabolic hormone which is
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highly expressed in the placenta and regulates placental and fetal growth [14]. In the fetus, LEP
is suggested to play a role in fetal growth, angiogenesis, hematopoiesis, brain development, and
immunity [14]. Recent studies have associated changes in LEP methylation and expression with
fetal growth, SGA, FGR, and neurodevelopmental outcome [6,7,15–19]. So far, methylation of
LEP and its relation to the CPR has not been investigated. LEP is a possibly important hormone
to investigate in FGR since short- and long-term adverse effects of FGR include obesity, meta-
bolic syndrome, and diabetes. Altered methylation and/or expression of LEP may contribute
to the susceptibility of FGR infants to these diseases. PHLDA2 is a well-known maternally
expressed imprinted gene, which represses placental growth. This highlights the important bal-
ance of PHLDA2 needed for optimal fetal growth. Various studies have reported overexpression
of this gene in SGA placentas and association with (low) birth weight, while others did not
report a significant difference [20,21]. Overexpression has also been associated with reduced
fetal movements followed by SGA, further emphasizing the clinical relevance of PHLDA2 [22].
DHCR24 encodes for an enzyme that catalyzes the final step in the synthesis of cholesterol.
Cholesterol is essential for cell membranes and critical for fetal development, particularly
brain development [23]. Furthermore, DHCR24 has an anti-apoptotic effect on neurons, is
thought to be neuroprotective, and its expression is down-regulated in SGA placentas [24].
In this study, our aim was to investigate whether methylation of selected angiogenic and
neurodevelopmental genes differs between SGA placentas with normal or abnormal Doppler
fetal hemodynamics, expressed as a normal/abnormal CPR. This seems to be the case for
VEGFA and LEP methylation. It is of clinical importance to discern the presence of brain-spar-
ing with the CPR in these SGA placentas as this indicates a compensatory mechanisms to pla-
cental insufficiency which is considered to give rise to fetal programming.
Materials and methods
Study population
We performed a prospective observational cohort study from June 2012 until September 2014 at
the Obstetrics and Neonatology Departments of the University Medical Center Groningen
(UMCG). The study was approved by the Institutional Review Board of the UMCG and written
informed consent was obtained from the mothers of the 48 SGA fetuses that were included [25].
SGA was defined as an estimated fetal weight below the 10th percentile or deflecting fetal growth
of at least 30 percentiles. Exclusion criteria adopted were: multiple pregnancy; structural and chro-
mosomal abnormalities; and intrauterine infection. All deliveries and admissions to the neonatal
ward/neonatal intensive care unit took place in the UMCG. In our study 41 of the SGA cases were
included, based on availability of both placental tissue and CPR data. Embedded paraffin slices of
placental tissue from this cohort were stored at the UMCG. Usage of the samples was approved by
the UMCG Medical Ethical Committee in line with the code of conduct for responsible use.
Selection of genes and primer design
We selected biologically relevant genes involved in placental/fetal growth, angiogenesis or neu-
rodevelopment. The genomic target region (Table 1) was chosen based on existing literature
regarding regulation by methylation and/or association with SGA, FGR, or PE.
The analyzed EPO promoter region has been reported to repress transcription via hyper-
methylation in cancer [26] and contains a hypoxia-inducible factor-1B binding site [27]. The
selected HIF1A promoter region contains a hypoxia response element that is thought to facili-
tate positive HIF1A autoregulation via hypomethylation [28], and a kaiso binding site-3 sug-
gested to mediate methylation-dependent HIF1A repression [27]. The VEGFA region has been
studied by Sundrani et al. who reported hypomethylation in PE placentas [13]. Our LEP region
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overlaps the promoter region investigated by Lesseur and colleagues which is regulated by
methylation [29–31]. Hypermethylation of the selected PHLDA2 promoter region silences
expression [32]. For DHCR24 we selected a cytosine-phosphate-guanosine (CpG) dinucleo-
tides-rich promoter region reported to regulate transcription via methylation [33].
All PCR and sequencing primers (Table 1) were designed with the PyroMark Assay Design
software (Qiagen, Hilden, Germany) and a gene specific biotinylated reversed/forward primer
approach was used to label the PCR product with biotin. For bisulfite amplification we pre-
pared a mastermix containing 12.5 μL HotStarTaq DNA Polymerase, 10.5 μL sterile water and
a 1 μL mix of forward and reverse primer (10:10 μM) per 1 μL bisulfite template. We included
a mastermix negative control to check for contamination. Cycling conditions on the T100
Thermal Cycler (Bio-Rad, Hercules, CA) were the same for all assays except for HIF1A: 95˚C
for 15 min, 45 cycles of 94˚C for 30 s, 58˚C (HIF1A 56˚C) for 30 s, 72˚C for 30 s, followed by a
final step of 72˚C for 7 min and stored at 4˚C. A DNA ladder and 3–5μL of each PCR product
was loaded and run on 2% agarose gel with ethidium bromide staining to visualize presence or
absence of PCR products and contamination.
Placenta was processed by investigators unaware of the clinical data. First, the fetal side was
selected by our pathologist on a hematoxylin-eosin stained section. Cores with a diameter of
1mm from the fetal side were used for DNA isolation with the QIAamp DNA FFPE (Forma-
lin-Fixed, Paraffin-Embedded) Tissue Kit (Qiagen). The FFPE tissue protocol is designed for
sections of 5–10μm and was adapted for 1mm cores. This entailed vortexing the samples at
step 3 for 1 minute and crushing the cores manually with a pipet tip. Quality and concentra-
tion of the isolated DNA was checked with the NanoDrop1ND-1000 spectrophotometer
(Thermo Fisher Scientific, Waltham, MA). Samples were stored at -20˚C.
For bisulfite conversion, we used the EZ methylation Gold-Kit (Zymo Research, Irvine,
CA) according to the supplier’s protocol with an additional 30s centrifuge round at full speed
after step 8. Samples were divided in two separate batches for adequate desulphonation time,
random and blinded. In total, 500 nanograms of each DNA sample was bisulfite converted for
subsequent analysis by pyrosequencing.
Quantification of methylation via pyrosequencing
We used the PyroMarkQ48 Autoprep (Qiagen) for pyrosequencing, according to the supplier’s
protocol. Methylation levels were analyzed with PyroMark Q48 Advanced Software (Qiagen).
Each of the CpG sites were quality control checked and the percentage of DNA methylation at
a given CpG calculated. CpGs that passed the quality check were included in data-analysis.
Excluded samples were repeated.
Doppler ultrasound
Doppler parameters of the UmbA and MCA were measured once a week prior to maternal
admission to the hospital and twice a week for the duration of admission by two experienced
operators, as described elsewhere [25]. The CPR was calculated as MCA-PI divided by
UmbA-PI. CPR data was transformed to z-scores as appropriate for the gestational age-specific
mean [25]. A CPR of<1 was considered abnormal. For data analysis, we used the last mea-
sured CPR before delivery, with a maximum of seven days prior to birth.
Statistical analysis
We assessed normality with the Shapiro-Wilk test, data with a Shapiro-Wilk p-value of< .05
was considered to follow a non-normal distribution. A parametric or non-parametric
approach was chosen as appropriate for the data. Continuous variables were compared using
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Student’s T-test or Mann-Whitney U test, categorical data with Chi-square or Fisher’s Exact
test, and correlations with Pearson’s Test or Spearman’s Rho. We used simple and multiple lin-
ear regression analyses to analyze independent associations between variables. For this, non-
normal distributed data were logarithmically transformed. A p-value of< .05 (two-tailed) was
considered statistically significant. Descriptive statistics are presented as mean (SD), median
(range), or frequency (%). We used the software Statistical Package for the Social Sciences
(SPSS) 23.0 for statistical analyses.
Results
Characteristics of the study population
The study cohort consisted of 48 SGA patients of whom we selected 41 based on availability of
both placenta material and CPR data. Patients were divided in two groups based on a normal (>1)
or abnormal (<1) CPR (Table 2). The groups significantly differed in gestational age at the time of
Doppler scan as well as at birth. Birth weight, birth weight percentile and head circumference were
smaller in the abnormal CPR group. The use of antenatal steroids was significantly higher in the
abnormal CPR group (82%) compared with cases with normal CPR (29%). All infants in the
abnormal CPR group were delivered via caesarean section compared to 42% of infants with a nor-
mal CPR. Apgar scores and venous pH were also lower for infants with an abnormal CPR. Dura-
tion of admission to the neonatal ward/neonatal intensive care unit was significantly longer, and
more often complicated by Respiratory Distress Syndrome or sepsis in the abnormal CPR group.
Average methylation of selected genes
We calculated the average methylation for each of the six genes (Table 3) after assessing the
correlation coefficients (S2 Table) between individual CpGs within one gene. We observed a
marginal non-significant trend toward hypermethylation on average (p = .095) for VEGFA in
the abnormal CPR group. For LEP we found an average difference between the groups of 2.5%
(95% CI: 0.5 to 5), (U = 118, z = -2.28, p = .023). Average methylation of EPO, HIF1A,
PHLDA2 and DHCR24 did not differ between groups.
Methylation of individual VEGFA and LEP CpGs
For VEGFA and LEP we compared the median or mean differences, depending on the normal-
ity of the distribution, at the individual CpGs between the CPR groups. Because of the mar-
ginal trend toward significance for the average methylation of VEGFA we analyzed all 3 CpGs
individually (Fig 1, S1 Table). We intended to also analyze another CpG locus on VEGFA in
close proximity to the transcription site, but were unable to design primers of high enough
quality for analysis. Of these sites, only CpG-1 (-309) methylation showed a statistically signifi-
cant increase of 0.74% (95% CI: 0.328% to 1.15%) in the abnormal CPR group, t(39) = 3.635,
p = .001 (Fig 1B). This is a medium effect size (Cohen’s d = 0.642). LEP showed a trend
towards higher methylation in the normal CPR group at all CpGs (Fig 2, S1 Table). Of these,
CpG-2 and CpG-11 were statistically significantly different between CPR groups. Mean meth-
ylation at CpG-2 was 5.96% (95% CI: 0.014 to 11.91) higher for normal CPR than abnormal
CPR, t(32) = -2.042, p = .049 (Fig 2B) and median methylation at CpG-11 was 7.99% (95% CI:
1.18 to 14.52) higher (U = 116, z = -2.33 p = .020; Fig 2C).
Association between CPR z-score and VEGFA/LEP methylation
To determine whether DNA methylation gradually changed as the CPR-z score deviated more
from zero, we analyzed the association between the CPR z-score and methylation of VEGFA
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PLOS ONE | https://doi.org/10.1371/journal.pone.0221972 August 30, 2019 6 / 16
Table 2. Maternal and fetal/neonatal characteristics.
Patient Characteristics Normal CPR Abnormal CPR P-value
N 24 17
Maternal
Age (years) 30.7 (23.2–40.6) 29.7 (23.6–39.5) .930 a
BMI (kg/m2) 22 (17.7–36) 24.4 (19.1–34.7) .570 b
Ethnicity (Caucasian) 19 (79.2) 16 (-94.1) .373 d
PE 3 (12.5) 4 (-23.5) .421 d
HELLP 3 (12.5) 0 (0) .254 d
PPROM 2 (8.3) 0 (0) .502 d
Oligohydramnios 15 (62.5) 10 (58.8) .812 c
Antenatal steroids 7 (29.2) 14 (82.4) < .001 c
(Stopped) smoking 12 (50) 7 (41.2) .676 d
Mode of delivery (SC) 10 (41.7) 17 (100) < .001 c
Fetal/Neonatal
GA Doppler (weeks) 36.6 (27.1–39.2) 30.4 (25.6–37) < .001 b
GA Birth (weeks) 37 (28–40) 31 (26–37) < .001 b
Gender (Boys) 8 (33.3) 9 (52.9) .335 c
Birth weight (grams) 2075 (700–3035) 905 (560–1980) < .001 a
Birth weight z-score -1.35 (-3.17–0.04) -1.72 (-2.74 - -0.98) .060 b
Birth weight percentile 9 (1–52) 4 (1–16) .045 b
Head circumference
(cm)
30 (23–34) 25.5 (21.2–32.5) .004 b
Apgar1’ 8 (2–9) 6 (2–9) .018 b
Apgar5’ 9 (5–10) 7 (4–10) .008 b
Apgar10’ 9 (7–10) 8.5 (4–10) .046 b
Venous pH 7.28 (7.16–7.41) 7.25 (7.02–7.31) .029 b
Arterial pH 7.23 (6.88–7.35) 7.2 (7.04–7.26) .195 b
Base excess (mmol/l) -6 (-10 - -1) -4 (-11 - -2) .867 a
Duration of admission
(days)
4.5 (0–48) 18 (2–90) .007 b
Complications
RDS 3 (12.5) 9 (52.9) .007 c
BPD 1 (4.2) 3 (17.6) .290 d
NEC 0 (0) 2 (11.8) .166 d
IVH 0 (0) 3 (17.6) .064 d
Sepsis 0 (0) 4 (23.5) .024 d
Mechanical ventilation 7 (29.2) 8 (47.1) .328 c
Characteristics given as median and (min-max) or frequency (%).
Abbreviations: Body Mass Index (BMI), Preeclampsia (PE), Hemolysis Elevated Liver enzymes and Low Platelets
(HELLP), Preterm premature rupture of the membranes (PPROM), Cesarean Section (SC), Gestational age (GA),
Respiratory Distress Syndrome (RDS), Bronchopulmonary Dysplasia (BPD), Necrotizing Enterocolitis (NEC),
Intraventricular hemorrhage (IVH)
a Student’s T-test
b Mann-Whitney U Test
c Chi-square Test
d Fisher’s Exact Test.
https://doi.org/10.1371/journal.pone.0221972.t002
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or LEP with Spearman’s rank-order correlation. Because the CPR is not constant throughout
gestation we used the CPR-z score. The average methylation of VEGFA, CpG-2, or CpG-3 did
not correlate with the CPR z-score, however, VEGFA CpG-1 correlated negatively with CPR
z-score, rho = -0.360, p = .021 (Fig 3A). The average methylation of LEP, and LEP CpG-2 did
not correlate statistically significant (rho = .253, p = .11 and rho = .07, p = .693, respectively).
LEP CpG-11 revealed a statistically significant positive correlation with the CPR z-score, rho
(39) = .350, p = .025 (Fig 3B).
Relationship between placental methylation CPR z-score, birth weight, and
antenatal steroids
Because of the differences between the CPR groups in gestational age, birth weight z-score,
and antenatal steroid usage we further investigated the influence of these parameters on the
significantly altered CpGs: LEP CpG-2, LEP CpG-11 and VEGFA CpG-1.
Table 3. Average methylation of the selected genes.
Gene CpGs Normal CPR Abnormal CPR P-value c
EPOa 1–6 4.3 (3.4–6.0) 4.3 (3.3–7.7) .979
HIF1Aa 1–7 4.1 (2.5–5.3) 4.2 (2.9–5.6) .347
VEGFAa 1–3 3.6 (3.0–5.4) 4.16 (3.1–5.1) .095
LEPa 1–13 20.0 (13.2–31.6) 17.5 (10.1–26.4) .023 �
PHLDA2a 1–4 16.3 (6.6–37.6) 17.5 (6.9–34.4) .916
DHCR24b 1, 2, 4–8 7.2 (4.6–11.4) 7.2 (5.7–4.6) .388
Values shown as median (range)
a n = 24, n = 17
b n = 22, n = 16
c Mann-Whitney U Test
� significant at the .05 level (2-tailed)
https://doi.org/10.1371/journal.pone.0221972.t003
Fig 1. Methylation of VEGFA for normal and abnormal CPR. Mean shown for CpG-1 (-309) & CpG-2 (-313) and median for CpG-3 (-331). And C; boxplot with
5–95 percentile whiskers mean methylation of VEGFA CpG-1 (-309). Double asterisk (��) indicates significance of p<0.01.
https://doi.org/10.1371/journal.pone.0221972.g001
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Simple linear regression analyses did not reveal a relationship between methylation of LEP
CpG-2 or VEGFA CpG-1 and gestational age, birth weight z-score, or antenatal steroid use.
The CPR z-score predicted LEP CpG-11 methylation statistically significant, F(1, 39) = 4.699,
p = .036, which explained 10.8% of the variance in methylation. Antenatal steroid use was asso-
ciated with LEP CpG-11 methylation, F(1, 39) = 4.995, p = .031, and explained 11% of the
variance in methylation. Gestational age was not associated with LEP CpG-11 methylation,
F(1,39) = 2.498, p = .122. As gestational age was closely related to antenatal steroid use we
decided not to enter gestational age in the multivariate model to avoid multicollinearity.
Multiple linear regression analyses
Simple linear regression analysis showed a statistically significant relation between LEPCpG-11
methylation, CPR z-score and the use of antenatal steroids. Therefore, we entered CPR z-score and
Fig 2. Methylation of LEP for normal and abnormal CPR. A; Methylation levels of LEP represented relative to the Transcription Start Site (TSS). CpG-1 (-127),
CpG-2 (-123), CpG-3 (-118), CpG-4 (-115), CpG-5 (-100), CpG-6 (-95), CpG-7 (-85), CpG-8 (-74), CpG-9 (-71), CpG-10 (-62), CpG-11 (-51), CpG-12 (-38), CpG-
13 (-33). Values are mean or median methylation as given in S1 Table. BC; boxplots with 5–95 percentile whiskers. B; Mean methylation of LEP CpG-2 (-123).
Normal CPR (N = 20) Abnormal CPR (N = 14). C; Median methylation of LEP CpG-11 (-51). Asterisk (�) indicates significance of p<0.05.
https://doi.org/10.1371/journal.pone.0221972.g002
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antenatal steroid use in a multiple regression model for the prediction of methylation. With both
variables included, the predictive value of the model was statistically significant F(2,38) = 3.310, p =
.047. This combined model explained 14.8% of the variance in LEPCpG-11 methylation.
Discussion
Fetal programming might take place in response to the adverse in-utero environment such as
in FGR, which has implications for the short-term as well as long-term health outcome. In this
study, we investigated fetal programming of selected angiogenic and neurological genes. We
analyzed methylation of EPO, HIF1A, VEGFA, LEP, PHLDA2 and DCHR24 in SGA placentas
and found differential methylation of VEGFA and LEP depending on the presence of brain-
sparing, defined as an abnormal CPR (<1). Average methylation levels of EPO, HIF1A,
PHLDA2 and DCHR24 did not differ between SGA with or without an abnormal CPR. Com-
parison of average VEGFA methylation showed a marginal tendency towards significance
between groups and CpG-1 (VEGFA-309) was significantly hypermethylated in the abnormal
CPR group. For LEP, we observed an overall hypomethylation, and at the specific CpGs: CpG-
2 (LEP-123) and CpG-11 (LEP-51) in the abnormal CPR group.
We found a decrease in methylation of 2.5% on average, 6% at CpG-2, and 8% at LEP CpG-
11 in the abnormal CPR group. Methylation of CpG-11 is of special interest because this CpG
is located at a binding site for CCAAT/enhancer binding protein-α (CEBPA), a principal regu-
lator of adipocyte differentiation and function [30]. Binding of CEBPA at this site highly acti-
vates transcription of LEP [31]. Methylation at this CpG results in transcriptional repression
[29–31]. SGA infants with an abnormal CPR might thus have increased levels of Leptin in
their placentas due to hypomethylation in the LEP region, specifically at CpG-11.
Recent studies have associated differential LEP expression and methylation with fetal
growth, SGA, and neurodevelopmental outcome [6,7,15–19]. Lea et al. demonstrated less
intense presence of Leptin in placentas from FGR singletons and growth-restricted infants in
twin pregnancies [6]. Another study reported increased LEP expression in FGR [17]. Lazo-de-
la-Vega-Monroy et al. support this by reporting elevated placental Leptin concentrations in
SGA which was inversely correlated with placental weight [7]. In contrast to the elevated pla-
centa levels, they showed that cord blood levels of Leptin and placental LEP receptor expres-
sion was lower in SGA, which both correlated positively with placental weight. Our findings
Fig 3. Spearman correlation coefficients (rho) and associated p-values provided for the association between and DNA methylation and CPR z-score. VEGFA
CpG-1 (A), LEP CpG-11 (B). Asterisk (�) indicates significance of p<0.05.
https://doi.org/10.1371/journal.pone.0221972.g003
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are in line with the reported elevation of Leptin concentration [7,17], and is contradicting with
decreased levels in SGA (9). Lesseur et al. investigated methylation of CpG-85 until CpG-33, as
in the present study (CpG-7 to CPG-13), and did not observe an association between placental
LEP methylation and birth weight [15]. They did find, however, an association between DNA
methylation and LEP expression in their cohort. Disagreements between Lesseur et al. and our
findings could result from our study-design. Our cohort consisted only of SGA cases and we
compared methylation based on their CPR while Lesseur and colleagues compared placental
methylation of SGA with appropriate-for-gestational age (AGA) fetuses.
Several potential confounders might have influenced our findings, as these were different
between cases with abnormal and normal CPR, including antenatal steroids and gestational
age at birth. Antenatal steroids were administered more often in the abnormal CPR group.
Linear regression analyses revealed that both the CPR z-score and antenatal steroids were asso-
ciated with LEP CpG-11 methylation. Both remained independent and significant predictors
in the combined multivariate regression analysis. We were not able to discern exactly how
much methylation was explained by which parameter in this small cohort because a large
majority of the abnormal CPR group had received antenatal steroids. The observed hypo-
methylation and hypothesized elevated LEP expression could also be in line with the effects of
antenatal betamethasone, as this is known to increase placental LEP concentrations [34]. Dif-
ferences in methylation might also partly be explained by differences in gestational age
between groups as it is known that gestational age is an important determinant of expression
of leptin in placenta and of maternal leptin concentrations [35]. Placental LEP expression is
higher and LEP receptors are less abundant in early pregnancy which could fit with the
observed hypomethylation of LEP in the abnormal CPR group having a lower gestational age
[36]. Therefore, we examined gestational age in our single and multiple regression analysis
and found that this was not predictive of LEP CpG-11 methylation.
VEGFA was hypermethylated at CpG-1 in the abnormal CPR group. This specific CpG is a
known binding site for HIF1A, an important pro-angiogenic factor which is beneficial in the acute
response to hypoxia [13]. VEGFA is also a key-player in the anti-hypoxic response as it stimulates
endothelial cell proliferation. This suggests that VEGFA is less expressed in the placenta of fetuses
with an abnormal CPR because methylation can repress VEGFA expression [37]. The observed
hypomethylation can be a sign of compensation to hypoxic stress in fetuses with a normal CPR, or
that these fetuses were constitutionally small and not in a distressed and hypoxic state.
Differential methylation of VEGFA CpG-1 is of importance with regard to emerging pre-
clinical research in placenta-directed gene therapy for FGR [38]. If this gene therapy would
reach the clinical stage, assessment of VEGFA methylation in fetal cells derived from the
maternal blood might be used to identify fetuses that could potentially benefit from placenta-
directed gene therapy such as adenovirus vectors containing VEGFA. Again, the altered meth-
ylation status of VEGFA is the set-point of methylation throughout life which might predispose
to the development of cardiovascular disease.
Our results suggest that adverse intrauterine conditions due to FGR and an abnormal CPR
alter methylation of LEP and VEGFA. These altered methylation levels are a reflection of intra-
uterine conditions and represent the level of placental LEP and VEGFA during gestation. The
placenta regulates its own growth and that of the fetus via LEP. Therefore, one might speculate
that altered LEP levels are part of FGR pathophysiology. Altered LEP levels may dysregulate
the development of important fetal endocrine feedback systems that regulate metabolism and
adipose tissue differentiation. Furthermore, LEP may play a role in neuronal functional differ-
entiation, glial development and development of the hippocampus and the cingulate cortex
which might affect memory and cognition [39]. Altered LEP levels during fetal development
might thus have an effect on memory, motor, and cognitive abilities.
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Another function of placental LEP is immunomodulation which is essential for maintaining
placental function at the interface between mother and her allogeneic fetus. With regard to
immunomodulation, both hypomethylated LEP and hypermethylated VEGFA could contrib-
ute to low-grade inflammation. Although mostly known for its pro-angiogenic activity,
VEGFA has an immunosuppressive role by inhibiting T-cell and dendritic cell development,
and stimulating regulatory T-cells (Tregs) and myeloid-derived suppressor cells [40]. In con-
trast, LEP is a powerful pro-inflammatory hormone which can activate the innate and adaptive
immune response [41]. LEP inhibits differentiation of Tregs and drives macrophage polariza-
tion to the inflammatory M1 phenotype. Extrapolating the hypo- and hypermethylation of
LEP and VEGFA, respectively, this would suggest an increased set-point for LEP and decreased
VEGFA levels in SGA fetuses with brain-sparing. These changes combined may predispose the
infant and later adult, to a pro-inflammatory epigenetic profile that cannot easily be altered.
Fetal programming may make ex-FGR infants susceptible to impaired neurodevelopment and
a state of chronic low-grade inflammation, associated with metabolic syndrome, diabetes mel-
litus type 2 and cardiovascular disease [42].
Our study has several strengths. For the first time, we investigated methylation in an SGA
cohort in relation to the CPR. This study is an extension of a well-designed prospective cohort
study for which numerous clinical parameters were meticulously recorded [25]. Categorizing
the SGA group depending on CPR allowed us to investigate methylation changes depending
on severity of FGR and brain-sparing instead of the association between SGA and methylation
in general. We adopted a gene specific approach and analyzed methylation levels of six gene
promoter areas based on existing literature. Although this is a limited selection in comparison
with genome-wide methylation profiling, this gave us the advantage of focusing on biologically
relevant genes.
We also recognize some limitations. First of all, because the placentas were embedded in
paraffin, we were not able to connect our methylation data with quantitative gene expression
outcomes. Other researchers, however, have previously studied the association between DNA
methylation and gene expression. The VEGFA region studied by us is a CG-rich promotor
region in close proximity to the transcription start site which is associated with gene repression
[43]. Induction of targeted DNA methylation of the VEGFA promoter by Siddique et al. demon-
strates that VEGFA expression is repressed by increasing amounts of DNA methylation [37].
The association between LEP methylation and expression has also been thoroughly studied
[31]. Negative associations with gene expression have been found in the maternal and fetal
side of the placenta [18,44]. In line with this, methylation of a larger LEP promoter region in
which our 13 investigated CpGs are located was also correlated with gene expression in the
white adipose tissue visceral adipocyte fraction [45]. This relationship was explored further in
a functional experiment where DNA methylation was inhibited in cultured human primary
skin fibroblasts and HeLa cells which resulted in increased LEP expression [45].
The negative associations described here fit with the theory that increased gene promotor
DNA methylation of LEP and VEGFA results in decreased expression. We expect that this rela-
tionship also exists within our cohort and assume that this could have an effect on gene
expression.
Second, we studied a small sample size and the variation in gestational age at birth was
great. Additionally, with this study design we cannot conclude whether the observed methyla-
tion changes are adaptive or maladaptive in the fetal period or thereafter, but the presence of a
difference suggests that altered programming occurs in the placenta of FGR fetuses with an
abnormally reduced CPR antenatally. Whether the observed differences in DNA methylation
are sufficient to alter gene expression enough to cause a physiological effect could be explored
further in an animal model of fetal brain-sparing.
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Conclusion
In conclusion, this study demonstrates that LEP and VEGFA are differentially methylated in
SGA placentas, depending on the CPR. This suggests that the presence of FGR as defined by
the CPR influences the epigenetic profile of the placenta differently. The increased risk of car-
diovascular disease and metabolic syndrome are known consequences of FGR. Clearly, more
research is needed to investigate the clinical significance of altered placental LEP, VEGFA, and
other genes in relation to clinical care of growth-restricted children who will develop into
adulthood. This study adds to the growing body of evidence regarding epigenetic program-
ming in FGR. With increasing knowledge of the placenta and its epigenetic profile, the pla-
centa can care for and protect the fetus throughout pregnancy and beyond birth by providing
physicians with the methylation status at birth. This methylation profile might be used as a
prognostic tool for targeted preventive interventions in the future.
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